Adynxx, Inc. (ADYX)

Market Cap	6.00
Revenue (ttm)	n/a
Net Income (ttm)	-10.57M
Shares Out	5.81M
EPS (ttm)	-1.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	183
Average Volume	3
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	-15.80
RSI	6.05
Earnings Date	n/a

About Adynxx

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: ADYX